initi outperform target price
robot surgeri improv spine growth drive higher
robot surgeri rs disrupt bil spine market
one two compani lead charg addit signific
commerci impact robot relat pull-through implant new
product improv rep retent product also help drive
share gain spine market one highest convict
outperform name recommend stock current level
sustain ebitda margin growth
record ebitda margin distinguish among smid-cap
comp averag posit ebitda
estim gmed core ebitda margin actual
bp reinvest growth program robot trauma
ou expans gmed margin profil disciplin reinvest model
along brisk pace innov product launch help
compani deliv above-market growth year
expect chang
rebound gmed valuat mid- upper teen
hard miss howev stock trade slightli
high-growth high-margin comp sale growth
ebitda margin includ
rs continu ramp could see upsid target multipl
valuat target price base project ebitda
bil trade one turn current multipl ntm
ebitda risk includ key product delay unexpect volum declin
 spine market potenti new litig regulatori qualiti
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag decemb
globu medic global manufactur provid wide
array medic devic equip treatment spinal
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
mariu zoican univers toronto rotman school manag decemb
initi coverag outperform rate price
outperform rate base above-market spine growth steadi flow new
product introduct continu placement adopt implant pull-thru
compani excelsiusgp robot surgeri system spine sustain
ebitda margin in-lin manag year histori profit growth
disciplin expens control partial off-set invest futur growth opportun
manag salesforc expans improv rep retent pay
manag step invest salesforc past month
improv sale rep retent rate begin pay dividend new
rep ramp new territori disrupt relat rep-turnov among
excelsiusgp robot gain traction healthi cadenc enhanc come
launch compani robot surgeri system last year cap three-year
develop effort compani follow acquisit project earli
face much larger robot surgeri competitor greater
resourc scale capit equip sale believ compani hold
check surgeon suggest view competit slightli
better area mdt mazor robot importantli estim robot
spine surgeri market remain earli stage robot penetr comfort
conserv assum target hospit penetr
robotically-plac implant around target robot surgeri spine
lumbar fusion complex spine pleas see sector launch report
disrupt alpha detail robot spine surgeri model earli stage
given competit two lead robot expect robot spine surgeri
compani continu rapidli expand instal base util robot
effect creat new robotically-placed-impl segment within spine
expect increasingli problemat time spine implant manufactur
record ebitda margin remain impress see
ebitda margin impress uniqu among smid-cap medic
devic compani unpreced base understand analysi
core margin estim manag reinvest model
long-term growth driver robot surgeri trauma intern view
compani margin quit sustain page summari discuss
analysi addit basic compon analysi follow page
would also note compani manufactur in-sourc initi provid
anoth bit tailwind compani profit model provid headroom
 invest also help off-set steadi headwind price
compani also face consist past year
globu medic global manufactur provid wide array medic devic
equip treatment spinal disord target price base
project ebitda bil trade one turn current
multipl ntm ebitda risk includ key product delay unexpect volum declin
 spine market potenti new litig regulatori qualiti issu
addit detail pleas see industri report disrupt alpha
mariu zoican univers toronto rotman school manag decemb
target
question face
despit invest emerg technolog
found object reach cash flow break-even year
ascend ebitda compani maintain past
year continu see compani comfort maintain ebitda
emerg
technolog robot trauma busi lower
corpor ebitda margin confid base estim
compani core busi gener ebitda margin creat
headroom manag invest growth opportun compani believ
help sustain extend above-averag growth next sever year
manag philosophi fuel invest expans intern market
develop robot surgeri platform creation trauma franchis
expect help diversifi extend compani growth profil analysi
view gmed margin summar
near-term despit
estim compani invest bp build ou
busi distribut network japan well key countri
australia germani itali expect compani continu invest
ou busi penetr market drive intern growth
turn expect drive improv sale growth margin region
scale compani also invest emerg technolog busi
consist robot trauma excelsiusgp robot platform receiv fda
approv august compani made inroad place robot
robot place estim also build trauma busi
focus inventori build sale forc build ahead roll-out
estim peg total invest around basic math ww
ebitda margin ebitda margin less invest ou
emerg technolog ebitda margin compani adher
busi model year expect chang
mariu zoican univers toronto rotman school manag decemb
placement number excelsiusgp robot place key stock driver
capit sale tend lumpi variabl around placement howev tend
histor strong capit placement expect number robot place
fourth quarter improv sequenti number robot place increas
also expect growth implant pull-through result better top-lin perform
ebitda margin consist deliv ebitda margin also key
stock driver ebitda margin includ drag owe increas
invest associ emerg technolog robot trauma
compani continu guid ebitda rang
continu top-lin out-performance mark fourth consecut quarter
double-digit organ growth reflect strength base busi well contribut
new product launch implant pull-through excelsiusgp continu top-
line perform level also key stock driver
robot placement pull-through result expect gain insight
number excelsiusgp robot system place result implant pull-through
compani report result earli view robot placement
import catalyst well key stock driver
resolut warn letter octob compani receiv warn letter
fda result inspect april facil biolog
texa san antonio texa letter describ observ non-conform
regul human cell tissu cellular tissue-bas product relat one
allograft tissu product process human biolog texa sold
compani expect materi impact financi result work
respons fda resolut warn letter would posit catalyst
increas competit ww spine market establish player failur
deliv ebitda margin addit could slower-than-expect
uptak new product includ excelsiusgp robot guidanc navig
mariu zoican univers toronto rotman school manag decemb
overview major busi line
organ two main segment spine emerg
technolog follow overview major busi line size
geograph mix growth profil well primari competitor key product
figur sale profit major busi line
sale geographi
figur overview major busi line
design hold individu
vertabr bodi bone
spine place long enough fuse
togeth treat deform
degener tumor
navig system ortho
neurosurg procedur
tot
line spine impant elsa line
signifi line biolog product
tot
captiv line compress
screw line fixat
plate arbor line extern
mariu zoican univers toronto rotman school manag decemb
estim coverag
return above-market
growth core
margin
robot
figur coverag univers glanc
mariu zoican univers toronto rotman school manag chart
figur growth turn corner robot add booster beyond
post
five quarter row
growth four
consecut quarter
double-digit
sale growth fall
due
disrupt sale
product relat
figur strong ebitda compar smid-cap peer
ebitda margin
significantli
peer
remark
bp
margin annual
manag made
mid- long-term
surgeri began
launch
 late
ahead smid cap med-tech peer
note peer group includ
mariu zoican univers toronto rotman school manag figur take share spine market
return
above-market growth
spine improv
sale rep retent
product
pull-through robot
drive gain
recov driven
stabil
re-align us
figur emerg growth product drive growth
contribut
busi
forecast rise
driven
larg
excelsiusgp
adjac
contribut risesto
driven robot
surgeri trauma
mariu zoican univers toronto rotman school manag figur free larg balanc fund emerg
balanc use
invest
penetr japan
tuck
strong rise balanc
provid flexibl continuedstrateg
invest tuck-in
mariu zoican univers toronto rotman school manag decemb
growth sustain ebitda margin
target price base ev/ebitda multipl project
ebtida mil trade one turn current multipl
outperform rate reflect above-market spine growth steadi flow new product
introduct continu placement adopt implant pull-thru compani
excelsiusgp robot surgeri system spine sustain ebitda
margin in-lin manag year histori profit growth disciplin
expens control partial off-set invest futur growth opportun fda
approv excelsiusgp recoveri spine busi stock recov
discount rose low-teen multipl ebitda late last year sinc
put four consecut quarter double-digit organ growth reflect strength
base busi pull-through excelsiusgp stock multipl risen
ntm ebitda view slightli high-growth high-margin
comp current trade
compani robot surgeri platform continu ramp could potenti see upsid
target multipl given premium histor award robot surgeri stock
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv growth high-growth
segment grow growth grow
grey one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv growth high-growth
segment grow growth grow
mariu zoican univers toronto rotman school manag decemb
risk target price rate includ follow
increas competit ww spine market compani compet
mani compani ww spine market includ larg player
johnson johnson stryker compani strength devic innov
acceler time-to-market respons surgeon enabl take
share larger player ww spine market increas competit renew
focu larger player could slow even revers share gain result
materi advers impact price perform sharehold return
persist declin ebitda margin compani consist deliv
ebitda margin far ahead smid-cap spine peer failur deliv
ebitda margin could materi advers effect compani
result materi advers impact price perform sharehold return
potenti delay failur clinic timelin regulatori approv
reimburs pipelin product compani launch
product sinc incept launch new product alon includ
compani excelsiusgp robot guidanc navig system compani also
current potenti new product variou stage develop
plan launch five ten new product annual come three year
failur bring new product market quickli improv exist product may
result compani fail achiev long-term financi goal compani
product becom obsolet custom switch competit product
could materi impact compani revenu profit
unfavor result unforeseen circumst relat compani
clinic program could result delay failur regulatori approv new
product plan modif indic expans exist product
addit chang insur coverag polici reimburs regulatori
chang relat compani product procedur could neg impact
compani busi potenti advers event challeng materi
impact oper cost potenti sale growth compani
product patent litig exposur product liabil claim patient other
may result costli litig loss revenu product recal brand impair
could materi advers effect compani addit patent
infring claim compani initi compani third
parti could also result costli time-consum litig potenti delay
product develop market
new fda quality-rel issu extend remedi fda warn
letter gmed product regul fda non-compli
regulatori requir could result potenti warn letter warn letter
could result signific modif compani oper potenti recal
inabl obtain futur pre-market approv remov current product
market remedi warn letter consist comprehens
plan correct action could drawn materi advers effect
compani term addit remedi cost potenti delay
disrupt product approv avail octob compani receiv
warn letter fda result inspect april facil
human biolog texa san antonio texa letter describ observ
non-conform regul human cell tissu cellular tissue-bas
product relat one allograft tissu product process human biolog
texa sold compani expect materi impact
financi result work respons fda
mariu zoican univers toronto rotman school manag decemb
current price emb long-term sale growth expect
assum annual margin improv
ran market-impli scenario use forecast holt dcf
assum annual margin improv solv sale
compound-annual-growth-rate requir justifi current price
sensit tabl figur help quantifi impact increment margin
growth valuat sensit top-lin growth everi
increment ad per share vs per share ad increment margin
current share price
step assum annual margin increas
step solv lt sale compound-annual-growth-rate requir get current price
base cs forecast deriv long term
assumpt market impli expect
valuat sensit top line growth everi
increment margin
assumpt methodolog
ebitda margin base cs research assum
increas annual
sale growth base cs research solv
sale compound-annual-growth-rate requir get current price
explicit forecast holt methodolog calcul
termin valu fade return capit growth toward cost
capit growth respect
mariu zoican univers toronto rotman school manag decemb
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
mariu zoican univers toronto rotman school manag statement project
sbc opex
mariu zoican univers toronto rotman school manag figur globu medic detail revenu model
motion
mariu zoican univers toronto rotman school manag decemb
short-term inv
prepaid exp
accum comp inc loss
mariu zoican univers toronto rotman school manag figur globu medic statement flow
chang work capit
prepaid asset
cf oper
chang invest
chang restreict cash
use invest
proce debt
payment debt
net stock issuanc option
repurchas common share
financ
effect fx
net chang cash
mariu zoican univers toronto rotman school manag decemb
compani mention price
